Robot surgery gets a High-Tech eye: new fusion imaging targets prostate cancer

NCT ID NCT07272317

Not yet recruiting Disease control Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial tests a new imaging system that combines PSMA-PET, MRI, and ultrasound to guide robot-assisted prostate surgery. The goal is to help surgeons remove all cancer while sparing healthy tissue, nerves, and urinary control. About 98 men with prostate cancer will take part to see if this approach lowers the chance of leftover cancer cells and speeds up recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PSMA-PET/MRI-ultrasound multimodal fusion navigation system
What this could lead to: If successful, this could make prostate cancer surgery more precise, reducing the chance of leftover cancer cells and helping men recover urinary control faster.
What could go wrong: This is an early-stage trial with only 98 participants, so results may not apply to everyone. The technology is complex and may not work as well in real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Shanghai General Hospital

Shanghai, Shanghai Municipality, 200080, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.